QuidelOrtho Announces New R&D Executive Leader

Rhea-AI Summary

QuidelOrtho (Nasdaq: QDEL) has announced the appointment of Jonathan Siegrist, PhD, as its new Executive Vice President of Research and Development (R&D) and Chief Technology Officer (CTO), effective October 7, 2024. Siegrist brings over 15 years of experience in molecular diagnostics, microfluidic platforms, and biomedical engineering. He will lead QuidelOrtho's R&D strategy, focusing on menu expansion and advancing critical platforms.

Siegrist previously served as CTO and Head of Assay Research and Development at Cepheid and co-founded a diagnostics manufacturing company. He will report to Brian Blaser, President and CEO. Werner Kroll, Senior Vice President of R&D, will support the transition until his retirement in March 2025. QuidelOrtho aims to leverage Siegrist's expertise to enhance its position in immunoassay and molecular testing, as well as clinical labs and transfusion medicine solutions.

Positive

• Appointment of experienced industry leader as EVP of R&D and CTO
• Focus on menu expansion and advancing critical platforms
• Potential for innovation in immunoassay and molecular testing

Negative

• None.

Jonathan Siegrist appointed as EVP of R&D and CTO

SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in innovative diagnostic solutions, is pleased to announce the appointment of Jonathan Siegrist, PhD, as its new Executive Vice President of Research and Development (R&D) and Chief Technology Officer (CTO), effective as of October 7, 2024.

Jonathan Siegrist, EVP of R&D and CTO, QuidelOrtho (Photo: Business Wire)

Siegrist brings a wealth of industry expertise and leadership experience with over 15 years in molecular diagnostics, microfluidic platforms, and biomedical engineering. He most recently was the CTO and Head of Assay Research and Development at Cepheid. Prior to Cepheid, he co-founded a diagnostics manufacturing company.

Reporting to Brian Blaser, President and Chief Executive Officer, Siegrist will spearhead QuidelOrtho’s R&D strategy with a focus on menu expansion and advancing critical platforms. His leadership is expected to advance QuidelOrtho’s industry-leading expertise in immunoassay and molecular testing and award-winning solutions in clinical labs and transfusion medicine. Werner Kroll, Senior Vice President, R&D, will support a smooth leadership transition and related activities until his retirement in March 2025.

“QuidelOrtho is at a pivotal point in our history, and Jonathan’s deep industry knowledge and insights in assay R&D and proven leadership make him an excellent fit for this role. We are confident his innovative approach will help us navigate our current opportunities and lead the company to success,” said Brian Blaser, President and Chief Executive Officer, QuidelOrtho.

Siegrist holds a PhD and Master of Science from the University of California, Irvine, and a Bachelor of Science in Electrical Engineering from the University of California, Los Angeles. His career has been marked by successful leadership roles across multiple disciplines within R&D.

QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit www.quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook, and X.

About QuidelOrtho Corporation

QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.

Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic. So that patients, clinicians and health officials can spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence.

Building upon its many years of groundbreaking innovation, QuidelOrtho continues to partner with customers across the healthcare continuum and around the globe to forge a new diagnostic frontier. One where insights and solutions know no bounds, expertise seamlessly connects and a more informed path is illuminated for each of us.

Source: QuidelOrtho Corporation

View source version on businesswire.com: https://www.businesswire.com/news/home/20241009251239/en/

Investor Contact:

Juliet Cunningham

Vice President, Investor Relations

IR@QuidelOrtho.com

Media Contact:

D. Nikki Wheeler

Senior Director, Corporate Communications

media@QuidelOrtho.com

Source: QuidelOrtho Corporation

FAQ

When will Jonathan Siegrist join QuidelOrtho (QDEL) as EVP of R&D and CTO?

Jonathan Siegrist will join QuidelOrtho (QDEL) as Executive Vice President of Research and Development and Chief Technology Officer effective October 7, 2024.

What is Jonathan Siegrist's background before joining QuidelOrtho (QDEL)?

Before joining QuidelOrtho, Jonathan Siegrist was the CTO and Head of Assay Research and Development at Cepheid. He also co-founded a diagnostics manufacturing company and has over 15 years of experience in molecular diagnostics, microfluidic platforms, and biomedical engineering.

What will be Jonathan Siegrist's main focus at QuidelOrtho (QDEL)?

At QuidelOrtho (QDEL), Jonathan Siegrist will spearhead the company's R&D strategy with a focus on menu expansion and advancing critical platforms in immunoassay and molecular testing, as well as solutions for clinical labs and transfusion medicine.

When is Werner Kroll, current SVP of R&D at QuidelOrtho (QDEL), retiring?

Werner Kroll, Senior Vice President of R&D at QuidelOrtho (QDEL), will retire in March 2025. He will support a smooth leadership transition until then.